Alchemab Therapeutics
PrivateLast Round
Series A
Extension
Jul 9, 2026
Total Funding Raised
$116M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alchemab Therapeutics is a biotechnology company that develops novel therapeutic antibodies by analyzing patient antibody repertoires from disease-resilient individuals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alchemab Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Alchemab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jul 9, 2026 | ||||
| Series A Extension | Sep 9, 2025 | ||||
| Grant | Dec 16, 2022 | ||||
| Series A | Apr 15, 2021 | ||||
| Accelerator | May 12, 2020 |
Key People
Founding team and executive leadership
Alchemab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A Extension, Series A |
| SV Health Investors | Series A, Series A Extension, Seed |
| DCVC Bio | Seed, Series A Extension |
| Camford Capital | Series A |
| Lightstone Ventures | Series A, Series A Extension |
| British Business Bank | Series A Extension |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 17, 2026
Dr. Ulrich Wendt appointed as Chief Business Officer.
- Sep 10, 2025
Phase I trial started for antibody candidate ATLX-1282.
Alchemab Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alchemab Therapeutics's valuation, stock price, and market status.